Omeros (OMER) said Thursday that zaltenibart, its drug candidate to treat complement 3 glomerulopathy, or C3G, was granted rare pediatric disease designation from the US Food and Drug Administration.
C3G is a rare kidney disease mainly affecting children and young adults. With no approved treatment yet, C3G often leads to end-stage renal disease within 10 years of diagnosis, according to Omeros.
The company said phase 3 clinical trials for zaltenibart in C3G are set to begin in 2025.
The FDA previously granted zaltenibart an orphan drug designation for the treatment of paroxysmal nocturnal hemoglobinuria, a rare and fatal blood disease, with phase 3 studies to be initiated later this quarter, Omeros said.
The company's shares were up nearly 2% in recent trading.
Price: 4.20, Change: +0.07, Percent Change: +1.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.